Durvalumab

Common brands: Imfinzi, Imjudo, Carboplatin, Kyxata, Gemcitabine

Top reporter: Astrazeneca Pharmaceuticals Lp

Programmed Death Ligand-1 Blocker [EPC]Platinum-based Drug [EPC]CTLA-4-directed Blocking Antibody [EPC]Microtubule Inhibitor [EPC]Topoisomerase Inhibitor [EPC]
18,758
Total Reports
14,870
Serious Reports
5,823
Death Reports
30
Reported Reactions
Death Report Ratio: High (31.04%)

Patient Demographics

Male
10,110
Female
5,653

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Durvalumab.

# Reaction Reports % of Total
1 DEATH 3,526
22.0%
2 MALIGNANT NEOPLASM PROGRESSION 1,474
9.2%
3 PNEUMONITIS 844
5.3%
4 RADIATION PNEUMONITIS 801
5.0%
5 PYREXIA 598
3.7%
6 DIARRHOEA 580
3.6%
7 OFF LABEL USE 529
3.3%
8 INTERSTITIAL LUNG DISEASE 464
2.9%
9 DYSPNOEA 463
2.9%
10 PNEUMONIA 442
2.8%
11 FATIGUE 421
2.6%
12 RASH 411
2.6%
13 ASTHENIA 392
2.4%
14 NEUTROPHIL COUNT DECREASED 391
2.4%
15 ANAEMIA 385
2.4%
16 COLITIS 346
2.2%
17 DISEASE PROGRESSION 335
2.1%
18 PLATELET COUNT DECREASED 335
2.1%
19 METASTASES TO CENTRAL NERVOUS SYSTEM 325
2.0%
20 NAUSEA 307
1.9%
21 MYELOSUPPRESSION 305
1.9%
22 FEBRILE NEUTROPENIA 299
1.9%
23 THROMBOCYTOPENIA 289
1.8%
24 HYPOTHYROIDISM 286
1.8%
25 DECREASED APPETITE 272
1.7%
26 DRUG INEFFECTIVE 268
1.7%
27 MYOCARDITIS 245
1.5%
28 NEUTROPENIA 245
1.5%
29 VOMITING 243
1.5%
30 PLEURAL EFFUSION 219
1.4%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.